Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia
Nachtnebel A
Record ID 32012000300
English
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://eprints.hta.lbg.ac.at/937/1/DSD_HSO_Nr.04_Update2011.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/937/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.